Sechenov Medical Journal

Advanced search

Interdisciplinary problem of post-transplant diabetes mellitus: literature review


The number of transplantation and transplant survival rates increase steadily. Patients after solid organ transplantation re-ceive lifelong immunosuppressive therapy which may have adverse effects on carbohydrate and lipid metabolism. The most diabetogenic drugs are calcineurin inhibitors and corticosteroids. Posttransplant diabetes mellitus (PTDM) is hyperglycemia that meets American Diabetes Association and World Health Organization diabetes criteria for nontransplant patients and that was newly diagnosed after transplantation. PTDM may worsen both short-term and long-term transplantation outcomes so that the problem of timely diagnosis, proper treatment and prevention is critical. In early post-transplant period, transient hyperglycemia is found in the vast majority of patients; therefore, PTDM screening is carried out at least one month after transplantation. The gold standard test for PTDM diagnosis is oral glucose tolerance test. In the same time diagnostic value of hemoglobin A1C is limited. Lifestyle therapy and antidiabetic drugs are considered as possible preventive measures. Stress induced hyperglycemia management in solid organ recipients is the same with other surgical patients. Which organ was transplanted, patient characteristics and possible drug interactions with immunosuppressive therapy should be taken into account while managing PTDM. Blood pressure and lipid profile should be under control for comprehensive cardiovascu-lar risk reduction. It remains unclear which PTDM treatment and prevention strategy is the best and for better understanding interdisciplinary approach is needed.

About the Authors

A. V. Balashova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anastasiya  V.  Balashova, Assistant Professor, Endocrinology Department № 1

8/2, Trubetskaya str., Moscow, 119991

+7 (916) 102-67-60

V. R. Mustafina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Violetta  R.  Mustafina, Resident

8/2, Trubetskaya str., Moscow, 119991

I. V. Glinkina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Irina V. Glinkina, Cand. of Sci. (Medicine), Associate Professor, Endocrinology Department № 1

8/2, Trubetskaya str., Moscow, 119991


1. Gautier S.V., Chomyakov S.V. Donorstvo i transplantatsiya organov v Rossiiskoi Federatsii v 2019 godu. XII soobshchenie registra Rossiiskogo transplantologicheskogo obshchestva [Organ donation and transplantation in the Russian Federation in 2019. 12th report on register of the Russian Transplant Society]. Vestnik transplantologii I iskusstvennykh-organov = Russian Journal of Transplantology and Artificial Organs. 2020; 22(2): 8–34 (In Russian).

2. Wang J.H., Skeans M.A., Israni A.K. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016; 23(5): 281–286. PMID: 27742381

3. Stehlik J., Edwards L. B., Kucheryavaya A. Y., et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant. 2012 Oct; 31(10): 1052–1064. PMID: 22975095

4. Got’e S.V., Shevchenko A.O., Poptsov V.N. Patsient s transplantirovannym serdtsem. Rukovodstvo dlya vrachei po vedeniyu patsientov, perenesshikh transplantatsiyu serdtsa [Patient after heart transplantation. A guidance for doctors]. Moscow; Tver’: “TriadA”, 2014. 144 p. (In Russian).

5. Shivaswamy V., Boerner B., Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016 Feb; 37(1): 37–61. PMID: 26650437

6. Sharif A., Hecking M., de Vries A.P., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14(9): 1992–2000. PMID: 25307034

7. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF Consultation. Geneva, Switzerland: WHO; 2006. 50 p.

8. Park S.C., Yoon Y.D., Jung H.Y., et al. Effect of transient posttransplantation hyperglycemia on the development of diabetes mellitus and transplantation outcomes in kidney transplant recipients. Transplant Proc. 2015 Apr; 47(3): 666–671. PMID: 25891707

9. Boerner B., Shivaswamy V., Goldner W., Larsen J. Management of the hospitalized transplant patient. Curr Diab Rep. 2015 Apr; 15(4): 19. PMID: 25721247

10. Valderhaug T.G., Jenssen T., Hartmann A., et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009; 88(3): 429–434. PMID: 19667949

11. Jenssen T., Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019; 15(3): 172–188. PMID: 30622369

12. Novikova M.S., Allazova S.S., Kotenko O.N., Shilov E.M Posttransplantatsionnyi sakharnyi diabet u patsientov s allotransplantatsiei pochki [Post-transplantation diabetes mellitus in patients with kidney allotransplantation]. Klinicheskaya nefrologiya. 2018; 4: 20–24 (In Russian).

13. Prokopenko E.I., Vatazin A.V., Shcherbakova E.O. Posttransplantatsionnyi sakharnyi diabet u retsipientov renal’nogo transplantata: opyt odnogo tsentra [New-onset diabetes mellitus after kidney tranplatation: single center experience]. Nefrology. 2017; 21(6): 20–28 (In Russian).

14. Movchan E.A., Kim Yu.Yu., Ryabtseva E.P., Galkina E.V. Posttransplantatsionnyi sakharnyi diabet [Posttransplantation diabetes mellitus]. Journal of Siberian Medical Sciences. 2018; 4: 26–33 (In Russian).

15. Lane J.T., Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab. 2011; 96(11): 3289–3297. PMID: 22058376

16. Sharif A., Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2010; 6(7): 415–423. PMID: 20498675

17. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11): 866–875. PMID: 26377054

18. Dedov I.I., Shestakova M.V., Maiorov A.Yu., et al. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol’nym sakharnym diabetom [Standards of specialized diabetes care]. Ed. by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes mellitus. 2019; 22 (1S1): 1–144 (In Russian).

19. Hecking M., Haidinger M., Döller D., et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012; 23(4): 739–749. PMID: 22343119

20. Allison T.L. Immunosuppressive Therapy in Transplantation. Nurs Clin North Am. 2016 Mar; 51(1): 107–120. PMID: 26897428

21. Bloom R.D., Rao V., Weng F., et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002; 13(5): 1374–1380. PMID: 11961026

22. Øzbay L.A., Møller N., Juhl C., et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol. 2012; 73(4): 536–545. PMID: 21988494

23. Shivaswamy V., Bennett R.G., Clure C.C., et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Transl Res. 2014; 163(3): 221–231. PMID: 24361102

24. Tanimura J., Nakagawa H., Tanaka T., et al. The clinical course and potential underlying mechanisms of everolimusinduced hyperglycemia. Endocr J. 2019 Jul 28; 66(7): 615–620. PMID: 30982794

25. Sommerer C., Witzke O., Lehner F., et al. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol. 2018 Sep; 19(1): 237. PMID: 30231851

26. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009; 9(3): S1–155. PMID: 19845597

27. Lazareva K.E., Rzhevskaya O.N., Zagorodnikova N.V. Prichiny razvitiya i metody korrektsii posttransplantatsionnogo sakharnogo diabeta [The causes of development and methods of correction of post-transplant diabetes mellitus]. The Russian Journal of Transplantation. 2017; 9(4): 335–349 (In Russian).

28. Boudreaux J.P., McHugh L., Canafax D.M., et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987; 44(3): 376–381. PMID: 3307061

29. Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006; 69(3): 588–595. PMID: 16395250

30. Hermayer K.L., Egidi M.F., Finch N.J., et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab. 2012; 97(12): 4399–4406. PMID: 23074234

31. Morbitzer K.A., Taber D.J., Pilch N.A., et al. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clin Transplant. 2014; 28: 862–868. PMID: 24893750

32. Garcia C., Wallia A., Gupta S., et al. Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clin Transplant. 2013; 27(3): 444–454. PMID: 23574363

33. Vanhove T., Remijsen Q., Kuypers D., Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando). 2017; 31(2): 69–77. PMID: 27665059

34. Stephen J., Anderson-Haag T.L., Gustafson S., et al. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol. 2014; 40(6): 546–553. PMID: 25613554

35. Vest L.S., Koraishy F.M., Zhang Z., et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant. 2018; 32(8): e13302. PMID: 29851159

36. Haidinger M., Werzowa J., Hecking M., et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation – a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014; 14(1): 115–123. PMID: 24279801

37. Türk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006; 6(4): 842–846. PMID: 16539642

38. Haidinger M., Antlanger M., Kopecky C., et al. Posttransplantation diabetes mellitus: evaluation of treatment strategies. Clin Transplant. 2015; 29(5): 415–424. PMID: 25777150

39. Boerner B.P., Miles C.D., Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014; 2014: 617638. PMID: 24817885

40. Lane J.T., Odegaard D.E., Haire C.E., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011; 92(10): e56–57. PMID: 22067216

41. Strøm Halden T.A., Åsberg A., Vik K., et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant. 2014; 29(4): 926–933. PMID: 24452849

42. Gueler I., Mueller S., Helmschrott M., et al. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther. 2013; 7: 297–303. PMID: 23630415

43. Halden T.A.S., Egeland E.J., Åsberg A., et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. Diabetes Care. 2016; 39(4): 617–624. PMID: 26908914

44. Pinelli N.R., Patel A., Salinitri F.D. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013; 36(10): e171–172. PMID: 24065848

45. Vallon V., Gerasimova M., Rose M.A., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014; 306(2): F194–204. PMID: 24226524

46. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128. PMID: 26378978

47. Mahling M., Schork A., Nadalin S., et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res. 2019; 44(5): 984–992. PMID: 31437852

48. Rajasekeran H., Kim S.J., Cardella C.J., et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care. 2017; 40(7): e75–76. PMID: 28416475

49. Cehic M., Greenfield J., Hayward Ch., et al. Impact of empagliflozin for the treatment of diabetes mellitus after heart transplantation. Transplantation. 2018; 102(7): S88.

Supplementary files


Views: 992

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)